{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:09:48Z","timestamp":1793851788437,"version":"4.6.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 28768"],"award-info":[{"award-number":["IG 28768"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["123752K23"],"award-info":[{"award-number":["123752K23"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014804","name":"Neurofibromatosis Therapeutic Acceleration Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015521","name":"Stanford Maternal and Child Health Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Molecular Autism"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Noonan syndrome (NS) and Noonan syndrome with multiple lentigines (NSML) are neurodevelopmental conditions caused by genetic variants leading to upregulated signaling in the RAS-MAPK pathway. While previous research has focused on genetic variability in cognitive and cardiac phenotypes, behavioral phenotypes, and their correlations across genetic variants and within the\n                      <jats:italic>PTPN11<\/jats:italic>\n                      gene remain poorly characterized.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study included 121 individuals with NS (\n                      <jats:italic>PTPN11<\/jats:italic>\n                      : 88,\n                      <jats:italic>SOS1<\/jats:italic>\n                      : 18,\n                      <jats:italic>RAF1<\/jats:italic>\n                      : 6,\n                      <jats:italic>KRAS<\/jats:italic>\n                      : 2,\n                      <jats:italic>RIT1<\/jats:italic>\n                      : 3,\n                      <jats:italic>NRAS<\/jats:italic>\n                      : 2,\n                      <jats:italic>LZTR1<\/jats:italic>\n                      : 2,\n                      <jats:italic>SOS2<\/jats:italic>\n                      : 1) and seven individuals with NSML (\n                      <jats:italic>PTPN11<\/jats:italic>\n                      ), compared to age- and sex-matched typically developing (TD) (N\u2009=\u200971). Behavioral questionnaires assessed social responsiveness and ASD-related traits (using SRS-2), and emotional problems (using CBCL) to identify genetic variant-specific behavioral profiles. Biochemical profiling of SHP2 activity in\n                      <jats:italic>PTPN11<\/jats:italic>\n                      -associated NS variants examined genotype\u2013phenotype relationships.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared to TD individuals, those with\n                      <jats:italic>PTPN11<\/jats:italic>\n                      -associated NS, NSML, and\n                      <jats:italic>SOS1<\/jats:italic>\n                      -associated NS exhibited clinically elevated scores, indicating increased ASD-related behaviors, poorer social functioning, and heightened emotional problems. Genetic variant comparisons revealed that individuals with\n                      <jats:italic>PTPN11<\/jats:italic>\n                      -associated NS and NSML exhibited greater ASD-related challenges than those with\n                      <jats:italic>RAF1<\/jats:italic>\n                      . Individuals with NSML exhibit elevated attention problems compared to all other genetic groups. Logistic regression results suggested each one-unit increase in SHP2 fold activation for\n                      <jats:italic>PTPN11<\/jats:italic>\n                      -associated NS corresponded to a 64% higher likelihood of markedly elevated restricted and repetitive behaviors, suggesting genotype\u2013phenotype links.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>\n                      Small sample sizes for rarer variants, leading to unequal group sizes across subgroups, with\n                      <jats:italic>PTPN11<\/jats:italic>\n                      variants comprising most of the NS group. Future research should address these sampling constraints and conduct functional studies to clarify variant impacts. Longitudinal assessments could elucidate behavioral phenotype trajectories.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This study underscores the importance of genetic variant-specific research to understand unique behavioral phenotypes in NS and NSML. Our findings indicate a higher risk for ASD-related symptoms in\n                      <jats:italic>PTPN11<\/jats:italic>\n                      -associated NS and NSML compared to other variants. Additionally, individuals with\n                      <jats:italic>PTPN11<\/jats:italic>\n                      -associated NS and higher SHP2 fold activation exhibited greater impairments in restricted and repetitive behaviors, suggesting SHP2 activation variations may contribute to phenotypic variability. By linking ASD-related symptoms to biochemical predictors in\n                      <jats:italic>PTPN11<\/jats:italic>\n                      -associated NS, this study may inform future targeted treatment approaches.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13229-025-00681-1","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:33:28Z","timestamp":1760150008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Genotype\u2013phenotype correlations with autism spectrum disorder-related traits in Noonan syndrome and Noonan syndrome with multiple lentigines: a cross-sectional study"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6357-9721","authenticated-orcid":false,"given":"Chloe Alexa","family":"McGhee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5929-0651","authenticated-orcid":false,"given":"Julia R.","family":"Plank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7027-8196","authenticated-orcid":false,"given":"Luca","family":"Pannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odeya","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Fuhrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-8018","authenticated-orcid":false,"given":"Francesca Clementina","family":"Radio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5843-419X","authenticated-orcid":false,"given":"Simone","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-9672","authenticated-orcid":false,"given":"Marco","family":"Tartaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5661-8297","authenticated-orcid":false,"given":"Tamar","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"681_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40142-016-0100-7","volume":"4","author":"WE Tidyman","year":"2016","unstructured":"Tidyman WE, Rauen KA. Expansion of the RASopathies. Curr Genet Med Rep. 2016;4:57\u201364.","journal-title":"Curr Genet Med Rep"},{"key":"681_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1749-6632.2010.05790.x","volume":"1214","author":"M Tartaglia","year":"2010","unstructured":"Tartaglia M, Gelb BD. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci. 2010;1214:99\u2013121.","journal-title":"Ann N Y Acad Sci"},{"key":"681_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/ajmg.c.32012","volume":"190","author":"M Tartaglia","year":"2022","unstructured":"Tartaglia M, Aoki Y, Gelb BD. The molecular genetics of RASopathies: an update on novel disease genes and new disorders. Am J Med Genet C Semin Med Genet. 2022;190:425\u201339.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"681_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0140-6736(12)61023-X","volume":"381","author":"AE Roberts","year":"2013","unstructured":"Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet. 2013;381:333\u201342.","journal-title":"Lancet"},{"key":"681_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.beem.2010.09.002","volume":"25","author":"M Tartaglia","year":"2011","unstructured":"Tartaglia M, Gelb BD, Zenker M. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab. 2011;25:161\u201379.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"681_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1086\/341528","volume":"71","author":"MC Digilio","year":"2002","unstructured":"Digilio MC, Conti E, Sarkozy A, Mingarelli R, Dottorini T, Marino B, et al. Grouping of multiple-lentigines\/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet. 2002;71:389\u201394.","journal-title":"Am J Hum Genet"},{"key":"681_CR7","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1242\/dev.106310","volume":"141","author":"M Bonetti","year":"2014","unstructured":"Bonetti M, Paardekooper Overman J, Tessadori F, No\u00ebl E, Bakkers J, den Hertog J. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish. Development. 2014;141:1961\u201370.","journal-title":"Development"},{"key":"681_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-3-031-62945-7_5","volume-title":"The RASopathies","author":"MC Hodgson","year":"2024","unstructured":"Hodgson MC, Chennappan S, Kontaridis MI. Syndrome with Multiple Lentigines. In: Rauen KA, editor. The RASopathies. Cham: Springer; 2024. p. 107\u201332."},{"key":"681_CR9","first-page":"858","volume":"9","author":"CA McGhee","year":"2024","unstructured":"McGhee CA, Honari H, Siqueiros-Sanchez M, Serur Y, van Staalduinen EK, Stevenson D, et al. Influences of RASopathies on neuroanatomical variation in children. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024;9:858\u201370.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"681_CR10","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1093\/cercor\/bhy158","volume":"29","author":"EM Johnson","year":"2019","unstructured":"Johnson EM, Ishak AD, Naylor PE, Stevenson DA, Reiss AL, Green T. PTPN11 gain-of-function mutations affect the developing human brain, memory, and attention. Cereb Cortex. 2019;29:2915\u201323.","journal-title":"Cereb Cortex"},{"key":"681_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1601-183X.2008.00469.x","volume":"8","author":"EI Pierpont","year":"2009","unstructured":"Pierpont EI, Pierpont ME, Mendelsohn NJ, Roberts AE, Tworog-Dube E, Seidenberg MS. Genotype differences in cognitive functioning in Noonan syndrome. Genes Brain Behav. 2009;8:275\u201382.","journal-title":"Genes Brain Behav"},{"key":"681_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/jmedgenet-2013-101951","volume":"51","author":"B Adviento","year":"2014","unstructured":"Adviento B, Corbin IL, Widjaja F, Desachy G, Enrique N, Rosser T, et al. Autism traits in the RASopathies. J Med Genet. 2014;51:10\u201320.","journal-title":"J Med Genet"},{"key":"681_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/dmcn.12621","volume":"57","author":"EI Pierpont","year":"2015","unstructured":"Pierpont EI, Tworog-Dube E, Roberts AE. Attention skills and executive functioning in children with Noonan syndrome and their unaffected siblings. Dev Med Child Neurol. 2015;57:385\u201392.","journal-title":"Dev Med Child Neurol"},{"key":"681_CR14","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1111\/dmcn.15627","volume":"65","author":"PE Naylor","year":"2023","unstructured":"Naylor PE, Bruno JL, Shrestha SB, Friedman M, Jo B, Reiss AL, et al. Neuropsychiatric phenotypes in children with Noonan syndrome. Dev Med Child Neurol. 2023;65:1520\u20139.","journal-title":"Dev Med Child Neurol"},{"key":"681_CR15","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1086\/340847","volume":"70","author":"M Tartaglia","year":"2002","unstructured":"Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet. 2002;70:1555\u201363.","journal-title":"Am J Hum Genet"},{"key":"681_CR16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/ng2073","volume":"39","author":"B Pandit","year":"2007","unstructured":"Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007;39:1007\u201312.","journal-title":"Nat Genet"},{"key":"681_CR17","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s10038-008-0343-6","volume":"53","author":"JM Ko","year":"2008","unstructured":"Ko JM, Kim J-M, Kim G-H, Yoo H-W. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome. J Hum Genet. 2008;53:999\u20131006.","journal-title":"J Hum Genet"},{"key":"681_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s40817-015-0005-5","volume":"2","author":"EI Pierpont","year":"2016","unstructured":"Pierpont EI. Neuropsychological functioning in individuals with Noonan syndrome: a systematic literature review with educational and treatment recommendations. J Pediatr Neuropsychol. 2016;2:14\u201333.","journal-title":"J Pediatr Neuropsychol"},{"key":"681_CR19","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/humu.20955","volume":"30","author":"A Sarkozy","year":"2009","unstructured":"Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, Pantaleoni F, et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat. 2009;30:695\u2013702.","journal-title":"Hum Mutat"},{"key":"681_CR20","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/ajmg.a.36374","volume":"164A","author":"P Alfieri","year":"2014","unstructured":"Alfieri P, Piccini G, Caciolo C, Perrino F, Gambardella ML, Mallardi M, et al. Behavioral profile in RASopathies. Am J Med Genet A. 2014;164A:934\u201342.","journal-title":"Am J Med Genet A"},{"key":"681_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164735","volume":"11","author":"E Wingberm\u00fchle","year":"2022","unstructured":"Wingberm\u00fchle E, Roelofs RL, Oomens W, Kramer J, Draaisma JMT, Leenders E, et al. Cognitive phenotype and psychopathology in Noonan syndrome spectrum disorders through various Ras\/MAPK pathway associated gene variants. J Clin Med. 2022;11:4735.","journal-title":"J Clin Med"},{"key":"681_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/ajmg.a.32488","volume":"149A","author":"L Cesarini","year":"2009","unstructured":"Cesarini L, Alfieri P, Pantaleoni F, Vasta I, Cerutti M, Petrangeli V, et al. Cognitive profile of disorders associated with dysregulation of the RAS\/MAPK signaling cascade. Am J Med Genet A. 2009;149A:140\u20136.","journal-title":"Am J Med Genet A"},{"key":"681_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/jmg.2006.046300","volume":"44","author":"M Zenker","year":"2007","unstructured":"Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, Koenig R, et al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet. 2007;44:131\u20135.","journal-title":"J Med Genet"},{"key":"681_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/ng1748","volume":"38","author":"S Schubbert","year":"2006","unstructured":"Schubbert S, Zenker M, Rowe SL, B\u00f6ll S, Klein C, Bollag G, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet. 2006;38:331\u20136.","journal-title":"Nat Genet"},{"key":"681_CR25","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jpeds.2011.05.024","volume":"159","author":"BH Lee","year":"2011","unstructured":"Lee BH, Kim J-M, Jin HY, Kim G-H, Choi J-H, Yoo H-W. Spectrum of mutations in Noonan syndrome and their correlation with phenotypes. J Pediatr. 2011;159:1029\u201335.","journal-title":"J Pediatr"},{"key":"681_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/ajmg.a.32115","volume":"146A","author":"W Verhoeven","year":"2008","unstructured":"Verhoeven W, Wingberm\u00fchle E, Egger J, Van der Burgt I, Tuinier S. Noonan syndrome: psychological and psychiatric aspects. Am J Med Genet A. 2008;146A:191\u20136.","journal-title":"Am J Med Genet A"},{"key":"681_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s11689-021-09414-w","volume":"14","author":"AMH Foy","year":"2022","unstructured":"Foy AMH, Hudock RL, Shanley R, Pierpont EI. Social behavior in RASopathies and idiopathic autism. J Neurodev Disord. 2022;14:5.","journal-title":"J Neurodev Disord"},{"key":"681_CR28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.biopsych.2024.09.019","volume":"97","author":"M Siqueiros-Sanchez","year":"2024","unstructured":"Siqueiros-Sanchez M, Serur Y, McGhee CA, Smith TF, Green T. Social communication in Ras pathway disorders: a comprehensive review from genetics to behavior in neurofibromatosis type 1 and Noonan syndrome. Biol Psychiatry. 2024;97:461\u201398.","journal-title":"Biol Psychiatry"},{"key":"681_CR29","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/dmcn.13394","volume":"59","author":"S Garg","year":"2017","unstructured":"Garg S, Brooks A, Burns A, Burkitt-Wright E, Kerr B, Huson S, et al. Autism spectrum disorder and other neurobehavioural comorbidities in rare disorders of the Ras\/MAPK pathway. Dev Med Child Neurol. 2017;59:544\u20139.","journal-title":"Dev Med Child Neurol"},{"key":"681_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.585700","volume":"11","author":"M-M Geoffray","year":"2020","unstructured":"Geoffray M-M, Falissard B, Green J, Kerr B, Evans DG, Huson S, et al. Autism spectrum disorder symptom profile across the RASopathies. Front Psychiatry. 2020;11:585700.","journal-title":"Front Psychiatry"},{"key":"681_CR31","doi-asserted-by":"crossref","unstructured":"Motta M, Flex E, Martinelli S, Tartaglia M. Molecular Genetics of Noonan Syndrome and Other RASopathies. The RASopathies: Genetic Syndromes of the RAS\/MAPK Pathway, Cham; Nature Switzerland: Springer; 2024. p. 263\u2013305.","DOI":"10.1007\/978-3-031-62945-7_12"},{"key":"681_CR32","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0092-8674(00)80938-1","volume":"92","author":"P Hof","year":"1998","unstructured":"Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE. Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998;92:441\u201350.","journal-title":"Cell"},{"key":"681_CR33","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ng772","volume":"29","author":"M Tartaglia","year":"2001","unstructured":"Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29:465\u20138.","journal-title":"Nat Genet"},{"key":"681_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000276766","volume":"1","author":"M Tartaglia","year":"2010","unstructured":"Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol. 2010;1:2\u201326.","journal-title":"Mol Syndromol"},{"key":"681_CR35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2007.03.027","volume":"54","author":"AS Gauthier","year":"2007","unstructured":"Gauthier AS, Furstoss O, Araki T, Chan R, Neel BG, Kaplan DR, et al. Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome. Neuron. 2007;54:245\u201362.","journal-title":"Neuron"},{"key":"681_CR36","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/humu.23175","volume":"38","author":"L Pannone","year":"2017","unstructured":"Pannone L, Bocchinfuso G, Flex E. Structural, functional, and clinical characterization of a novel PTPN11 mutation cluster underlying Noonan syndrome. Hum Mutat. 2017;38:451\u20139.","journal-title":"Hum Mutat"},{"key":"681_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1086\/499925","volume":"78","author":"M Tartaglia","year":"2006","unstructured":"Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V, et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet. 2006;78:279\u201390.","journal-title":"Am J Hum Genet"},{"key":"681_CR38","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jpeds.2003.11.032","volume":"144","author":"M Zenker","year":"2004","unstructured":"Zenker M, Buheitel G, Rauch R, Koenig R, Bosse K, Kress W, et al. Genotype-phenotype correlations in Noonan syndrome. J Pediatr. 2004;144:368\u201374.","journal-title":"J Pediatr"},{"key":"681_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12881-020-0986-5","volume":"21","author":"JP Athota","year":"2020","unstructured":"Athota JP, Bhat M, Nampoothiri S, Gowrishankar K, Narayanachar SG, Puttamallesh V, et al. Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations. BMC Med Genet. 2020;21:50.","journal-title":"BMC Med Genet"},{"key":"681_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41398-023-02504-4","volume":"13","author":"B Rai","year":"2023","unstructured":"Rai B, Naylor PE, Siqueiros-Sanchez M, Wintermark M, Raman MM, Jo B, et al. Novel effects of Ras-MAPK pathogenic variants on the developing human brain and their link to gene expression and inhibition abilities. Transl Psychiatry. 2023;13:245.","journal-title":"Transl Psychiatry"},{"key":"681_CR41","first-page":"146","volume":"9","author":"M Siqueiros-Sanchez","year":"2022","unstructured":"Siqueiros-Sanchez M, Rai B, Chowdhury S, Reiss AL, Green T. Syndrome-specific neuroanatomical phenotypes in girls with Turner and Noonan syndromes. Biol Psychiatry Cogn Neurosci Neuroimaging. 2022;9:146\u201355.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"681_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/hbm.70087","volume":"45","author":"JR Plank","year":"2024","unstructured":"Plank JR, Gozdas E, Dai E, McGhee CA, Raman MM, Green T. Elucidating microstructural alterations in neurodevelopmental disorders: application of advanced diffusion-weighted imaging in children with rasopathies. Hum Brain Mapp. 2024;45:e70087.","journal-title":"Hum Brain Mapp"},{"key":"681_CR43","doi-asserted-by":"crossref","unstructured":"Wechsler D. Wechsler Abbreviated Scale of Intelligence-Second Edition (WASI-II). NCS Pearson 2011.","DOI":"10.1037\/t15171-000"},{"key":"681_CR44","doi-asserted-by":"crossref","unstructured":"Wechsler D, Kaplan E, Fein D, Kramer J, Morris R, Delis D, et al. Wechsler intelligence scale for children. Pearson; 2003.","DOI":"10.1037\/t15174-000"},{"key":"681_CR45","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1023\/A:1025014929212","volume":"33","author":"JN Constantino","year":"2003","unstructured":"Constantino JN, Davis SA, Todd RD, Schindler MK, Gross MM, Brophy SL, et al. Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised. J Autism Dev Disord. 2003;33:427\u201333.","journal-title":"J Autism Dev Disord"},{"key":"681_CR46","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jpeds.2015.04.075","volume":"167","author":"JN Constantino","year":"2015","unstructured":"Constantino JN, Zhang Y, Holzhauer K, Sant S, Long K, Vallorani A, et al. Distribution and within-family specificity of quantitative autistic traits in patients with neurofibromatosis type I. J Pediatr. 2015;167:621-6.e1.","journal-title":"J Pediatr"},{"key":"681_CR47","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1007\/s11136-023-03397-y","volume":"32","author":"AJ Kaat","year":"2023","unstructured":"Kaat AJ, Croen LA, Constantino J, Newshaffer CJ, Lyall K. Modifying the social responsiveness scale for adaptive administration. Qual Life Res. 2023;32:2353\u201360.","journal-title":"Qual Life Res"},{"key":"681_CR48","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/00004583-199707000-00021","volume":"36","author":"J Kaufman","year":"1997","unstructured":"Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"681_CR49","unstructured":"Achenbach TM, Dumenci L, Rescorla LA. Ratings of relations between DSM-IV diagnostic categories and items of the CBCL\/6\u201318, TRF, and YSR. Burlington, VT: 2001."},{"key":"681_CR50","unstructured":"Coulacoglou C, Saklofske DH. Psychometrics and psychological assessment: Principles and applications. Academic Press; 2017."},{"key":"681_CR51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.rasd.2017.01.009","volume":"37","author":"CI Magyar","year":"2017","unstructured":"Magyar CI, Pandolfi V. Utility of the CBCL DSM-oriented scales in assessing emotional disorders in youth with autism. Res Autism Spectr Disord. 2017;37:11\u201320.","journal-title":"Res Autism Spectr Disord"},{"key":"681_CR52","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s10862-008-9119-8","volume":"31","author":"BJ Nakamura","year":"2009","unstructured":"Nakamura BJ, Ebesutani C, Bernstein A, Chorpita BF. A psychometric analysis of the child behavior checklist DSM-oriented scales. J Psychopathol Behav Assess. 2009;31:178\u201389.","journal-title":"J Psychopathol Behav Assess"},{"key":"681_CR53","doi-asserted-by":"publisher","first-page":"15973","DOI":"10.1021\/acs.jmedchem.1c01371","volume":"64","author":"S Bobone","year":"2021","unstructured":"Bobone S, Pannone L, Biondi B, Solman M, Flex E, Canale VC, et al. Targeting oncogenic Src homology 2 domain-containing phosphatase 2 (SHP2) by inhibiting its protein-protein interactions. J Med Chem. 2021;64:15973\u201390.","journal-title":"J Med Chem"},{"key":"681_CR54","doi-asserted-by":"publisher","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","volume":"50","author":"M Varadi","year":"2022","unstructured":"Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 2022;50:D439\u201344.","journal-title":"Nucleic Acids Res"},{"key":"681_CR55","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.2044-8317.2012.02047.x","volume":"66","author":"B Lantz","year":"2013","unstructured":"Lantz B. The impact of sample non-normality on ANOVA and alternative methods. Br J Math Stat Psychol. 2013;66:224\u201344.","journal-title":"Br J Math Stat Psychol"},{"key":"681_CR56","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.clpt.2004.11.112","volume":"77","author":"P He","year":"2005","unstructured":"He P, Court MH, Greenblatt DJ, Von Moltke LL. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther. 2005;77:373\u201387.","journal-title":"Clin Pharmacol Ther"},{"key":"681_CR57","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaad.2024.04.073","volume":"91","author":"JY So","year":"2024","unstructured":"So JY, Nazaroff J, Yenamandra VK, Gorell ES, Harris N, Fulchand S, et al. Functional genotype-phenotype associations in recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol. 2024;91:448\u201356.","journal-title":"J Am Acad Dermatol"},{"key":"681_CR58","first-page":"101","volume":"25","author":"A Vargha","year":"2000","unstructured":"Vargha A, Delaney HD. A critique and improvement of the CL common language effect size statistics of McGraw and Wong. J Educ Behav Stat. 2000;25:101\u201332.","journal-title":"J Educ Behav Stat"},{"key":"681_CR59","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/15374416.2019.1622121","volume":"49","author":"AS Young","year":"2020","unstructured":"Young AS, Youngstrom EA, Findling RL, Van Eck K, Kaplin D, Youngstrom JK, et al. Developing and validating a definition of impulsive\/reactive aggression in youth. J Clin Child Adolesc Psychol. 2020;49:787\u2013803.","journal-title":"J Clin Child Adolesc Psychol"},{"key":"681_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s11689-018-9239-8","volume":"10","author":"EI Pierpont","year":"2018","unstructured":"Pierpont EI, Hudock RL, Foy AM, Semrud-Clikeman M, Pierpont ME, Berry SA, et al. Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1. J Neurodev Disord. 2018;10:21.","journal-title":"J Neurodev Disord"},{"key":"681_CR61","volume-title":"Predictors of Social Functioning Outcomes in Children with RASopathies and Idiopathic Autism Spectrum Disorder","author":"AM Foy","year":"2021","unstructured":"Foy AM. Predictors of Social Functioning Outcomes in Children with RASopathies and Idiopathic Autism Spectrum Disorder. United States: The University of Wisconsin - Madison; 2021."},{"key":"681_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40817-020-00088-1","volume":"6","author":"KS Walsh","year":"2020","unstructured":"Walsh KS, del Castillo A, Kennedy T, Karim AI, Semerjian C. A review of psychological, social, and behavioral functions in the RASopathies. J Pediatr Neuropsychol. 2020;6:131\u201342.","journal-title":"J Pediatr Neuropsychol"},{"key":"681_CR63","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1172\/JCI44972","volume":"121","author":"TM Marin","year":"2011","unstructured":"Marin TM, Keith K, Davies B, Conner DA, Guha P, Kalaitzidis D, et al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest. 2011;121:1026\u201343.","journal-title":"J Clin Invest"},{"key":"681_CR64","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1128\/MCB.00646-09","volume":"30","author":"T Edouard","year":"2010","unstructured":"Edouard T, Combier JP, N\u00e9d\u00e9lec A, Bel-Vialar S, M\u00e9trich M, Conte-Auriol F, et al. Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase\/AKT\/glycogen synthase kinase 3\u03b2 signaling. Mol Cell Biol. 2010;30:2498\u2013507.","journal-title":"Mol Cell Biol"},{"key":"681_CR65","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","volume":"17","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005;17:596\u2013603.","journal-title":"Curr Opin Cell Biol"},{"key":"681_CR66","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/nn.3546","volume":"16","author":"M Costa-Mattioli","year":"2013","unstructured":"Costa-Mattioli M, Monteggia LM. mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nat Neurosci. 2013;16:1537\u201343.","journal-title":"Nat Neurosci"},{"key":"681_CR67","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s10880-019-09659-7","volume":"27","author":"RL Roelofs","year":"2020","unstructured":"Roelofs RL, Wingberm\u00fchle E, van der Heijden PT, Jonkers R, de Haan M, Kessels RPC, et al. Personality and psychopathology in adults with Noonan syndrome. J Clin Psychol Med Settings. 2020;27:256\u201367.","journal-title":"J Clin Psychol Med Settings"},{"key":"681_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s11689-017-9205-x","volume":"9","author":"T Green","year":"2017","unstructured":"Green T, Naylor PE, Davies W. Attention deficit hyperactivity disorder (ADHD) in phenotypically similar neurogenetic conditions: Turner syndrome and the RASopathies. J Neurodev Disord. 2017;9:25.","journal-title":"J Neurodev Disord"},{"key":"681_CR69","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejpn.2017.09.009","volume":"22","author":"F Perrino","year":"2018","unstructured":"Perrino F, Licchelli S, Serra G, Piccini G, Caciolo C, Pasqualetti P, et al. Psychopathological features in Noonan syndrome. Eur J Paediatr Neurol. 2018;22:170\u20137.","journal-title":"Eur J Paediatr Neurol"},{"key":"681_CR70","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1002\/ajmg.a.61361","volume":"179","author":"AM McNeill","year":"2019","unstructured":"McNeill AM, Hudock RL, Foy AMH, Shanley R, Semrud-Clikeman M, Pierpont ME, et al. Emotional functioning among children with neurofibromatosis type 1 or Noonan syndrome. Am J Med Genet A. 2019;179:2433\u201346.","journal-title":"Am J Med Genet A"},{"key":"681_CR71","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/ajmg.a.33268","volume":"152A","author":"EI Pierpont","year":"2010","unstructured":"Pierpont EI, Pierpont ME, Mendelsohn NJ, Roberts AE, Tworog-Dube E, Rauen KA, et al. Effects of germline mutations in the Ras\/MAPK signaling pathway on adaptive behavior: cardiofaciocutaneous syndrome and Noonan syndrome. Am J Med Genet A. 2010;152A:591\u2013600.","journal-title":"Am J Med Genet A"},{"key":"681_CR72","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3390\/genes12111746","volume":"12","author":"V Vasic","year":"2021","unstructured":"Vasic V, Jones MSO, Haslinger D, Knaus LS, Schmeisser MJ, Novarino G, et al. Translating the role of mTOR- and RAS-associated signalopathies in Autism Spectrum Disorder: Models, mechanisms and treatment. Genes (Basel). 2021;12:1746.","journal-title":"Genes (Basel)"},{"key":"681_CR73","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s13287-020-01775-8","volume":"11","author":"Y Ju","year":"2020","unstructured":"Ju Y, Park JS, Kim D, Kim B, Lee JH, Nam Y, et al. SHP2 mutations induce precocious gliogenesis of Noonan syndrome-derived iPSCs during neural development in vitro. Stem Cell Res Ther. 2020;11:282.","journal-title":"Stem Cell Res Ther"},{"key":"681_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008108","volume":"15","author":"MC Holter","year":"2019","unstructured":"Holter MC, Hewitt LT, Koebele SV, Judd JM, Xing L, Bimonte-Nelson HA, et al. The Noonan syndrome-linked Raf1L613V mutation drives increased glial number in the mouse cortex and enhanced learning. PLoS Genet. 2019;15:e1008108.","journal-title":"PLoS Genet"},{"key":"681_CR75","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11065-018-9380-x","volume":"28","author":"AK Chisholm","year":"2018","unstructured":"Chisholm AK, Anderson VA, Pride NA, Malarbi S, North KN, Payne JM. Social function and autism spectrum disorder in children and adults with neurofibromatosis type 1: a systematic review and meta-analysis. Neuropsychol Rev. 2018;28:317\u201340.","journal-title":"Neuropsychol Rev"},{"key":"681_CR76","unstructured":"Adam NB, Amemiya AR, Wallace SE, Mahon CT, Mirzaa GM, Adam MP. Evaluation of targeted therapies currently available for congenital genetic conditions indexed in GeneReviews. Am J Med Genet. C Semin Med Genet. 2025:e32137."},{"key":"681_CR77","volume":"2012","author":"TI Winarni","year":"2012","unstructured":"Winarni TI, Schneider A, Borodyanskara M, Hagerman RJ. Early intervention combined with targeted treatment promotes cognitive and behavioral improvements in young children with fragile x syndrome. Case Rep Genet. 2012;2012:280813.","journal-title":"Case Rep Genet"},{"key":"681_CR78","doi-asserted-by":"publisher","first-page":"1213410","DOI":"10.3389\/fnins.2023.1213410","volume":"17","author":"LA Milla","year":"2023","unstructured":"Milla LA, Corral L, Rivera J, Zu\u00f1iga N, Pino G, Nunez-Parra A, et al. Neurodevelopment and early pharmacological interventions in fragile X syndrome. Front Neurosci. 2023;17:1213410.","journal-title":"Front Neurosci"},{"key":"681_CR79","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/jcpp.12801","volume":"58","author":"AJ Kaat","year":"2017","unstructured":"Kaat AJ, Farmer C. Commentary: Lingering questions about the Social Responsiveness Scale short form. A commentary on Sturm et al. (2017). J Child Psychol Psychiatry. 2017;58:1062\u20134.","journal-title":"J Child Psychol Psychiatry"}],"container-title":["Molecular Autism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13229-025-00681-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13229-025-00681-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13229-025-00681-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T03:03:32Z","timestamp":1771988612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13229-025-00681-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["681"],"URL":"https:\/\/doi.org\/10.1186\/s13229-025-00681-1","relation":{},"ISSN":["2040-2392"],"issn-type":[{"value":"2040-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"26 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Stanford University School of Medicine's Institutional Review Board. All procedures involving human participants follow the institutional\/national committees and the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all participants included in this study.\n                      Consent for publication\n                      Written informed consent for publication was obtained from all participants (or their legal guardians).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"51"}}